2.98
Pliant Therapeutics Inc stock is traded at $2.98, with a volume of 1.70M.
It is down -1.97% in the last 24 hours and down -73.42% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$3.04
Open:
$3.06
24h Volume:
1.70M
Relative Volume:
1.38
Market Cap:
$181.34M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.9644
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+14.40%
1M Performance:
-73.42%
6M Performance:
-76.25%
1Y Performance:
-82.09%
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PLRX
Pliant Therapeutics Inc
|
2.98 | 181.34M | 5.03M | -185.41M | -139.79M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.11 | 118.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.00 | 74.34B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
639.00 | 38.83B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.00 | 32.36B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
122.75 | 29.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-09-24 | Resumed | Leerink Partners | Outperform |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
May-18-23 | Initiated | Canaccord Genuity | Buy |
Apr-13-23 | Initiated | Robert W. Baird | Outperform |
Dec-14-22 | Initiated | Stifel | Buy |
Dec-07-22 | Initiated | JP Morgan | Overweight |
Sep-01-22 | Initiated | Citigroup | Buy |
Jul-20-22 | Initiated | SVB Leerink | Outperform |
May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
Dec-10-21 | Initiated | Oppenheimer | Outperform |
Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
Nov-03-21 | Initiated | H.C. Wainwright | Buy |
Apr-20-21 | Initiated | BTIG Research | Buy |
Apr-05-21 | Initiated | Citigroup | Buy |
Jun-29-20 | Initiated | Citigroup | Buy |
Jun-29-20 | Initiated | Cowen | Outperform |
Jun-29-20 | Initiated | Needham | Buy |
Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - PR Newswire
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Pliant Therapeutics (PLRX) to Release Quarterly Earnings on Tuesday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation - Markets Insider
Pliant Therapeutics chief business officer Hull sells $178,500 in stock - MSN
Pliant Therapeutics' chief medical officer sells $206,973 in stock - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Reach Out - Markets Insider
What is HC Wainwright's Forecast for PLRX FY2029 Earnings? - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $10.00 at Needham & Company LLC - MarketBeat
Pliant Therapeutics' (PLRX) Market Perform Rating Reiterated at Oppenheimer - MarketBeat
Pliant Therapeutics Initiates Outside Expert Panel to Review BEACON-IPF Trial Data - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Given Hold Rating at Canaccord Genuity Group - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Reach Out - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pliant Therapeutics' chief human resource officer sells $41,892 in stock - MSN
Pliant Thera lines up experts to review BEACON-IPF Phase IIb/III trial - The Pharma Letter
Pliant Therapeutics stock hits 52-week low at $2.52 - MSN
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price - MarketBeat
Stifel maintains Pliant Therapeutics stock buy rating amid study pause By Investing.com - Investing.com Canada
Sector Update: Health Care Stocks Mixed Thursday Afternoon -February 13, 2025 at 02:03 pm EST - Marketscreener.com
Sector Update: Health Care Stocks Mixed Thursday Afternoon - TradingView
Pliant Therapeutics Moves Forward With Expert Panel Following BEACON-IPF Trial Enrollment Pause - Nasdaq
Sector Update: Health Care -February 13, 2025 at 01:45 pm EST - Marketscreener.com
Stifel maintains Pliant Therapeutics stock buy rating amid study pause - MSN
Pliant stock jumps 28% on bexotegrast study update - MSN
Pliant stock jumps 28% on bexotegrast study update (PLRX:NASDAQ) - Seeking Alpha
Pliant Therapeutics (NASDAQ:PLRX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - The Manila Times
Pliant Therapeutics Announces Next Steps Following DSMB - GlobeNewswire
Pliant's IPF Drug Trial Hits Unexpected Hurdle: Expert Panel Called for Urgent Review - StockTitan
What is HC Wainwright’s Estimate for PLRX FY2029 Earnings? - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year LowTime to Sell? - MarketBeat
Pliant Therapeutics stock hits 52-week low at $2.52 By Investing.com - Investing.com Nigeria
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 8.7%Should You Sell? - MarketBeat
Pliant Therapeutics, Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire
Pliant pauses mid-stage trial for lung disease therapy - MSN
Canaccord Genuity cuts Pliant to hold on study setback - MSN
Oppenheimer cuts Pliant Therapeutics stock rating amid trial pause - MSN
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 8.7%Should You Sell? - MarketBeat
Pliant stock plunges 61% amid study pause, downgrades - MSN
Citigroup Downgrades Pliant Therapeutics (PLRX) - MSN
Pliant Therapeutics Pauses Enrollment and Dosing in BEACON-IPF TrialOn February 7, 2025, Pliant Therapeutics, Inc. (NASDAQ: PLRX) disclosed that, subsequent to a prespecified data review and recommendations made by the trial’s independent Data Saf - Defense World
Canaccord Genuity cuts Pliant to hold on study setback (PLRX:NASDAQ) - Seeking Alpha
Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan - Yahoo Finance
Pliant Therapeutics (NASDAQ:PLRX) Downgraded by HC Wainwright to Neutral - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Lowered to Sector Perform Rating by Royal Bank of Canada - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Downgraded to “Equal Weight” Rating by Wells Fargo & Company - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Shares Up 6.7%Here's What Happened - MarketBeat
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):